Scilex Holding Co (SCLX): Cash & Equivalents
$4.96M
As of 2025-12-31
$566.0K
As of 2026-06-30
+31.4%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.96M | +51.4% | 2026-04-10, Balance as of period end |
| 2024-12-31 | $3.27M | -16.6% | 2026-04-10, Balance as of period end |
| 2023-12-31 | $3.92M | +79.5% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $2.18M | -49.7% | 2024-03-12, Balance as of period end |
| 2021-12-31 | $4.34M | n/m | 2023-03-07, Balance as of period end |
| 2020-12-31 | $30.5K | n/a | 2022-02-24, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Scilex Holding Co (SCLX) | 2025-12-31 | $4.96M | +51.4% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $110.82M | +29.0% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $217.05M | +289.7% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $74.60M | +34.4% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $41.72M | +52.3% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $357.01M | +196.9% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $20.95M | -50.0% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $65.30M | -8.5% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $146.65M | +11.5% |
Compare SCLX, DTIL, XFOR, CCCC side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗